Source: Annual Congress 2005 - New perspectives in asthma treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Naline, M. Molimard, R. Fairhurst, A. Trifilieff, C. Advenier (Paris, Bordeaux, France; Horsham, United Kingdom). Pharmacological characterization of indacaterol, a novel 24-hour β₂-agonist, on isolated human bronchus. Eur Respir J 2005; 26: Suppl. 49, 1398

Member's Comments

No comment yet.

Related content which might interest you: Duration and onset of action of indacaterol, a novel 24-hour β2-agonist, on isolated human bronchus Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005 Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi Source: Eur Respir J 2007; 29: 575-581 Year: 2007 Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2-agonist, on small airways in human and rat lung slices Source: Annual Congress 2006 - Novel treatments for asthma Year: 2006 Pharmacological characterization of the mechanism of action leading to synergism between glycopyrronium bromide and indacaterol fumarate Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007 Pharmacological characterization of CHF6162, a novel long acting inhaled corticosteroid for the treatment of asthma Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017 Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 Cardiovascular safety of indacaterol, a novel 24-hour β2-agonist, in patients with stable asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 An assessment of the functional profile of aclidinium in human bronchi and left atria Source: Annual Congress 2011 - Translational models of disease Year: 2011 Combination study of tiotropium and olodaterol in human precision-cut lung slices Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Indacaterol, a novel once-daily β2-agonist, provides effective 24-hour bronchodilation in moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Pharmacological interaction between glycopyrronium bromide and indacaterol fumarate on the human airways tone Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma Source: Eur Respir J 2007; 29: 871-878 Year: 2007 Pulmonary fibroblasts, an emerging target for bronchodilatory drug Source: Annual Congress 2009 - Translational models of lung disease Year: 2009 Cardiac safety of indacaterol, a novel once-daily bronchodilator, in COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Effect of aclidinium bromide, a novel long-acting anticholinergic, on salivation, colonic motility and faecal output in different animal models Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 Deposition and metabolism of inhaled ciclesonide in the human lung Source: Eur Respir J 2010; 36: 1113-1119 Year: 2010 Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Single-dose indacaterol, a novel 24-hour β2-agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005